Sarah Heeson

3.3k total citations · 1 hit paper
23 papers, 2.4k citations indexed

About

Sarah Heeson is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Sarah Heeson has authored 23 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Cancer Research. Recurrent topics in Sarah Heeson's work include HER2/EGFR in Cancer Research (21 papers), Breast Cancer Treatment Studies (7 papers) and Cancer Treatment and Pharmacology (7 papers). Sarah Heeson is often cited by papers focused on HER2/EGFR in Cancer Research (21 papers), Breast Cancer Treatment Studies (7 papers) and Cancer Treatment and Pharmacology (7 papers). Sarah Heeson collaborates with scholars based in United Kingdom, United States and Switzerland. Sarah Heeson's co-authors include Adele Murrell, Wolf Reik, Sandra M. Swain, Andreas Schneeweiß, José Baselga, Javier Cortés, Emma Clark, Mark Benyunes, Mario Campone and Jean-Marc Ferrero and has published in prestigious journals such as New England Journal of Medicine, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Sarah Heeson

22 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

2015 1.4k citations Sandra M. Swain, José Baselga et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah Heeson United Kingdom	11	1.5k	801	624	607	445	23	2.4k
Rashmi K. Murthy United States	24	2.3k 1.5×	644 0.8×	974 1.6×	839 1.4×	599 1.3×	85	2.9k
Debora Fumagalli Belgium	24	2.2k 1.5×	1.0k 1.3×	622 1.0×	279 0.5×	1.2k 2.8×	83	3.3k
Florence Lerebours France	29	1.4k 0.9×	915 1.1×	692 1.1×	322 0.5×	1.2k 2.7×	97	2.6k
Carrie A. Adelman United States	17	1.5k 1.0×	1.6k 1.9×	1.4k 2.3×	236 0.4×	729 1.6×	29	3.0k
Michael Burchmore United States	9	1.6k 1.0×	655 0.8×	291 0.5×	906 1.5×	352 0.8×	9	2.0k
Pamela Klein United States	12	770 0.5×	469 0.6×	301 0.5×	244 0.4×	247 0.6×	28	1.3k
P. Kelly Marcom United States	20	1.1k 0.8×	378 0.5×	304 0.5×	324 0.5×	669 1.5×	49	1.8k
Antonino Musolino Italy	22	1.3k 0.9×	598 0.7×	407 0.7×	730 1.2×	452 1.0×	89	2.1k
Kari B. Wisinski United States	23	987 0.7×	803 1.0×	340 0.5×	74 0.1×	426 1.0×	93	1.9k
Raushan T. Kurmasheva United States	27	814 0.5×	1.3k 1.6×	546 0.9×	56 0.1×	366 0.8×	120	2.3k

Countries citing papers authored by Sarah Heeson

Since Specialization

Citations

This map shows the geographic impact of Sarah Heeson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Heeson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Heeson more than expected).

Fields of papers citing papers by Sarah Heeson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Heeson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Heeson. The network helps show where Sarah Heeson may publish in the future.

Co-authorship network of co-authors of Sarah Heeson

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Heeson. A scholar is included among the top collaborators of Sarah Heeson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Heeson. Sarah Heeson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wynne, Chris, Bei Wang, Rong Deng, et al.. (2025). Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system. Journal of Cancer Research and Clinical Oncology. 151(6). 188–188.

Harper‐Wynne, Catherine, Yeon Hee Park, Fábio Franke, et al.. (2024). heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer. 24(1). 641–641. 4 indexed citations

Küemmel, Sherko, Catherine Harper‐Wynne, Fábio Franke, et al.. (2023). Abstract OT2-03-01: heredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection ± giredestrant (GDC-9545) for estrogen receptor+, HER2+ advanced breast cancer. Cancer Research. 83(5_Supplement). OT2–3. 2 indexed citations

Swain, Sandra M., Antoinette R. Tan, Luca Gianni, et al.. (2022). Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. European Journal of Cancer. 178. 70–81. 4 indexed citations

Tabernero, Josep, Paulo M. Hoff, Lin Shen, et al.. (2022). Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. Gastric Cancer. 26(1). 123–131. 35 indexed citations

Im, S-A., Antoinette R. Tan, André Mattar, et al.. (2021). 46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study. Annals of Oncology. 32. S40–S41. 4 indexed citations

Tabernero, Josep, Paulo M. Hoff, Lin Shen, et al.. (2020). 1423MO End-of-study analysis from JACOB: A phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC). Annals of Oncology. 31. S900–S901. 9 indexed citations

Tan, Antoinette R., Seock‐Ah Im, André Mattar, et al.. (2020). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet Oncology. 22(1). 85–97. 104 indexed citations

Tan, Antoinette R., Seock‐Ah Im, André Mattar, et al.. (2020). Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study. Cancer Research. 80(4_Supplement). PD4–7. 8 indexed citations

10.

Kirschbrown, Whitney P., Chris Wynne, Matts Kågedal, et al.. (2018). Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study. The Journal of Clinical Pharmacology. 59(5). 702–716. 28 indexed citations

11.

Swain, Sandra M., Andreas Schneeweiß, Luca Gianni, et al.. (2017). Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Annals of Oncology. 28(4). 761–768. 25 indexed citations

12.

Miles, David, et al.. (2017). Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Annals of Oncology. 28(11). 2761–2767. 9 indexed citations

13.

Urruticoechea, Ander, Mohammed Rizwanullah, Seock‐Ah Im, et al.. (2017). Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy. Journal of Clinical Oncology. 35(26). 3030–3038. 88 indexed citations

14.

Urruticoechea, Ander, Seock‐Ah Im, Montserrat Muñoz-Mateu, et al.. (2017). Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P).. Journal of Clinical Oncology. 35(15_suppl). 1023–1023. 4 indexed citations

15.

Swain, SM, Andreas Schneeweiß, Lorenzo Gianni, et al.. (2016). Abstract P4-14-14: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Cancer Research. 76(4_Supplement). P4–14. 2 indexed citations

16.

Urruticoechea, Ander, Mohammed Rizwanullah, Seock‐Ah Im, et al.. (2016). PHEREXA: A phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting.. Journal of Clinical Oncology. 34(15_suppl). 504–504. 10 indexed citations

17.

Swain, Sandra M., José Baselga, Sung‐Bae Kim, et al.. (2015). Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine. 372(8). 724–734. 1421 indexed citations breakdown →

18.

Miles, David, et al.. (2015). Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.. Journal of Clinical Oncology. 33(15_suppl). 598–598. 5 indexed citations

19.

Murrell, Adele, Sarah Heeson, & Wolf Reik. (2004). Interaction between differentially methylated regions partitions the imprinted genes Igf2 and H19 into parent-specific chromatin loops. Nature Genetics. 36(8). 889–893. 434 indexed citations

20.

Murrell, Adele, Sarah Heeson, Lucy Bowden, et al.. (2001). An intragenic methylated region in the imprinted Igf2 gene augments transcription. EMBO Reports. 2(12). 1101–1106. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact